<DOC>
	<DOCNO>NCT02605252</DOCNO>
	<brief_summary>As HBsAg clearance uncommon chronic hepatitis B ( CHB ) patient nucleoside analogue ( NAs ) therapy . The purpose study optimize HBsAg clearance CHB Patients sequential treatment pegylated interferon alpha-2b NAs .</brief_summary>
	<brief_title>New Strategy Study Functional Cure Chronic Hepatitis B</brief_title>
	<detailed_description>CHB Patients receive , respond , NAs 12 month switch receive peginterferon alfa-2b 80 micrograms/week 48 week follow 48 week .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>1 . CHB patient receive NAs 12 month . 2 . Hepatitis B e antigen ( HBeAg ) negative antiHBeAg positive . 3 . Hepatitis B surface antigen ( HBsAg ) positive &lt; 1500 IU/mL . 4 . Hepatitis B virus DNA detectable . 1 . Patients liver cirrhosis , Hepatocellular Carcinoma malignancy . 2 . Patients factor cause liver disease . 3 . Pregnant lactating woman . 4 . Patients concomitant HIV infection congenital immune deficiency disease . 5 . Patients diabetes , autoimmune disease . 6 . Patients important organ dysfunction . 7 . Patients serious complication ( e.g. , infection , hepatic encephalopathy , hepatorenal syndrome , gastrointestinal bleeding . ) 8 . Patients receive antineoplastic immunomodulatory therapy past 12 month . 9 . Patients ca n't come back clinic followup schedule .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Chronic hepatitis B</keyword>
	<keyword>Peginterferon alfa-2b</keyword>
	<keyword>Nucleotide analogue</keyword>
</DOC>